Jie Yang1,2, Xiaoyang Cui1, Jie Li1,3, Canfei Zhang1, Jing Zhang1, Ming Liu1. 1. a Department of Neurology , West China Hospital, Sichuan University , Chengdu , PR China . 2. b Department of Neurology , Nanjing First Hospital, Nanjing Medical University , Nanjing , PR China , and. 3. c Department of Neurology , People's Hospital of Deyang City , Deyang , PR China.
Abstract
AIMS: To assess the effectiveness of edaravone for acute stroke including ischemic stroke and intracerebral hemorrhage (ICH). METHODS: We identified randomized controlled trials with comprehensive searches and performed systematic reviews according to the Cochrane methods of systematical reviews. RESULTS: Edaravone can reduce the rate of death or long-term disability significantly for acute ischemic stroke (AIS) (RR = 0.65; 95%CI, 0.48 to 0.89, p = 0.007). However, sensitivity analysis yielded a different result. Edaravone can also improve the short-term neurological impairment of AIS (MD = 7.09; 95%CI, 5.12 to 9.05, p < 0.00001), and ICH (MD = -4.32; 95%CI, -5.35 to -3.29, p < 0.00001). CONCLUSIONS: Edaravone is beneficial in improving neurological impairment resulting from AIS and ICH. However, currently there is no enough convincing evidence that edaravone reduces death or long-term disability for AIS and ICH.
AIMS: To assess the effectiveness of edaravone for acute stroke including ischemic stroke and intracerebral hemorrhage (ICH). METHODS: We identified randomized controlled trials with comprehensive searches and performed systematic reviews according to the Cochrane methods of systematical reviews. RESULTS:Edaravone can reduce the rate of death or long-term disability significantly for acute ischemic stroke (AIS) (RR = 0.65; 95%CI, 0.48 to 0.89, p = 0.007). However, sensitivity analysis yielded a different result. Edaravone can also improve the short-term neurological impairment of AIS (MD = 7.09; 95%CI, 5.12 to 9.05, p < 0.00001), and ICH (MD = -4.32; 95%CI, -5.35 to -3.29, p < 0.00001). CONCLUSIONS:Edaravone is beneficial in improving neurological impairment resulting from AIS and ICH. However, currently there is no enough convincing evidence that edaravone reduces death or long-term disability for AIS and ICH.
Authors: Meenakshi Ahluwalia; Manish Kumar; Pankaj Ahluwalia; Scott Rahimi; John R Vender; Raghavan P Raju; David C Hess; Babak Baban; Fernando L Vale; Krishnan M Dhandapani; Kumar Vaibhav Journal: Neurochem Int Date: 2021-09-22 Impact factor: 3.921